ORIGINAL ARTICLE

Bioactive thionic compounds and aromatic glycosides from *Ligusticum chuanxiong*

Xu Zhang†, Bing Han†, Ziming Feng, Jianshuang Jiang, Yanan Yang, Peicheng Zhang⁎

*State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China*

Received 12 January 2018; received in revised form 15 March 2018; accepted 26 March 2018

**KEY WORDS**

*Ligusticum chuanxiong* Hort.; Thionic compounds; Aromatic glycosides; Anti-inflammatory; Natural products

**Abstract** Three new thionic compounds, (S)-2-(2-carboxyl-2-hydroxyethylthio)-ferulic acid (1), (E)-2-methoxy-4-[(3-methylsulfonyl)prop-1-en-1-yl]phenol (2), and thiosenkyunolide C (3), together with two new aromatic glycosides (4 and 5) were isolated from the rhizome of *Ligusticum chuanxiong* Hort. Two known compounds (6 and 7) were also obtained. Their structures were elucidated based on extensive spectroscopic data (UV, IR, 1D and 2D NMR, and HR-ESI-MS). Furthermore the absolute configurations were established by comparison of their calculated and experimental circular dichroism spectra and by a dimolybdenum tetraacetate [Mo2(AcO)4]-induced circular dichroism procedure. All compounds were evaluated against lipopolysaccharide (LPS)-induced NO production in BV2 cells, and compounds 4 and 5 showed strong inhibitory activities with IC50 values of 2.03 and 3.09 µmol/L, respectively (positive control curcumin, IC50 = 6.17 µmol/L). In addition, compound 1 showed weak protein tyrosine phosphatase-1B (PTP1B) inhibitory activity.

© 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

†Corresponding author. Tel.: +86 10 63165231; fax: +86 10 63017757.
E-mail address: pczhang@imm.ac.cn (Peicheng Zhang).

These authors made equal contributions to this work.

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.

https://doi.org/10.1016/j.apsb.2018.04.002

2211-3835 © 2018 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Thionic compounds are common heteroatomic compounds in plants. They have also been detected and isolated from food, fruits and wine1–7. Notably, they have been shown to possess various pharmacological activities, such as antifungal, anti-inflammatory, anti-helicobacter, antitumor, and antiparasitic activities, as well as being alternative carbonic anhydrase and neurosteroid-like inhibitors8–10. Chuanxiong, a famous traditional Chinese medicine, is derived from the rhizome of *Ligusticum chuanxiong* Hort. After years of research, Chuanxiong has been proven to possess various bioactivities, such as neuroprotective, anti-inflammatory, antimicrobial, and anti-proliferative effects15–18. In a recent report, several thionic phthalides were isolated from Chuanxiong. These novel compounds increased the diversity of the known phthalides in Chuanxiong.

To identify additional novel bioactive thionic compounds, the rhizome of *L. chuanxiong* was investigated. Herein, three new thionic compounds (1–3, Fig. 1) were successfully isolated. In addition, two new aromatic glycosides (4 and 5, Fig. 1) and two known aromatic glycosides (6 and 7) were also isolated. Evaluation of their bioactivity showed that compounds 4 and 5 had strong anti-inflammatory activity against LPS-induced NO production in BV2 microglial cells, and compound 1 showed weak PTP1B inhibitory activity.

2. Results and discussion

Compound 1 was obtained as a white, amorphous powder. The molecular formula was calculated to be C_{13}H_{14}O_{7}S from the positive HR-ESI-MS [M + H]^+ ion peak at *m/z* 315.0531 (Calcd. for 315.0533), suggesting the presence of 7 degrees of unsaturation. The 1H NMR resonances (Table 1) at δ_1H_1 7.44 (1H, d, J = 8.5 Hz, H-6), 6.89 (1H, d, J = 8.5 Hz, H-5), 8.18 (1H, d, J = 16.0 Hz, H-7), and 6.25 (1H, d, J = 16.0 Hz, H-8) suggested a tetrasisubstituted benzene ring and a trans double bond. In combination with the 13C NMR resonances (Table 1) at δ_13C_128.7, 130.2, 148.7, 152.3, 117.4, 123.3, 142.4, 117.8 and 167.8, these data indicated the presence of a tetrasisubstituted cinnamic acid group. Additionally, The HR-ESI-MS data indicated one S atom was present. In combination with the NMR data [δ_1H_3 3.12 (1H, dd, J = 4.5, 13.0 Hz, H-1’a), 2.97 (1H, dd, J = 8.0, 13.0 Hz, H-1’b), and 3.93 (1H, dd, J = 4.5, 8.0 Hz, H-2’), δ_13C_39.7, 69.7, and 173.9], a mercaptopropionic acid moiety was deduced, and it was attached at C-2 based on the correlation of H-1’-C-2 in the HMBC spectrum (Fig. 2). The correlation of H-OCH_3/C-3 confirmed that the methoxy was attached at C-3. Therefore, the planar structure of 1 was determined. The absolute configuration of C-2’ was established by a dimolybdene tetraacetate [Mo_2(AsO_4)]-induced circular dichroism procedure31. The diagnostic Cotton effect at approximately 342.5 nm was negative, which indicated the absolute configuration of C-2’ was S. Thus, the structure of 1 was confirmed as (S)-2-(2-carboxyl-2-hydroxyethylthio)-ferulic acid.

Compound 2 was obtained as a white, amorphous powder. The positive HR-ESI-MS gave a [M + Na]^+ ion peak at *m/z* 265.0504 (Calcd. for 265.0505), which was in accordance with an empirical molecular formula of C_{11}H_{14}O_{7}Na. The 1H NMR and 13C NMR spectra of 2 (Table 1) displayed an ABX system [δ_1H_7 7.05 (1H, d, J = 1.5 Hz, H-2), 6.89 (1H, dd, J = 8.0, 1.5 Hz, H-6), and 6.76 (1H, d, J = 8.0 Hz, H-5); δ_13C_110.6, 121.8, and 116.4]; a trans double bond [δ_1H_8 6.68 (1H, d, J = 16.0 Hz, H-7) and 6.11 (1H, dt, J = 16.0, 7.5 Hz, H-8); δ_13C_140.5 and 113.7]; a methylene [δ_1H_9 3.95 (2H, d, J = 7.5 Hz, H-9); δ_13C_59.6] and a methyl group [δ_1H_2 2.93 (3H, s, H-11); δ_13C_39.6]. Furthermore, a methoxy carbon was...

---

**Figure 1**  The structures of the isolated compounds 1–7.
observed at $\delta_C$ 56.5 (3'-OCH$_3$). A phenylpropanoid group was suggested by the correlations of H-5/C-1, H-6/C-4, H-7/C-2, H-8/C-1, and H-9/C-7 in the HMBC spectrum (Fig. 2). In conjunction with the key correlation of H-11/C-9, a methylsulfonyl moiety was confirmed, and the phenylpropanoid group was attached to the sulfur atom. Therefore, the structure of 2 was established as (E)-2-methoxy-4-(3-(methylsulfonyl)prop-1-en-1-yl)phenol.

Compound 3 was obtained as a white, amorphous powder, and its molecular formula was established as C$_{15}$H$_{20}$O$_6$S from its HR-ESI-MS peak at $m/z$ 329.1060 [M + H]$^+$ (Calcd. 329.1053). The bands in the IR spectrum at 3364, 1747 and 1631 cm$^{-1}$ suggested the presence of hydroxy, $\gamma$-lactone and diene groups, respectively. The $^1$H NMR spectrum (Table 1) show a double bond resonance at $\delta_H$ 5.46 (1H, t, $J = 8.0$ Hz, H-8), resonances for five methylene groups at $\delta_H$ 2.44, m (1H, t, $J = 8.0$ Hz, H-9), 1.82, m (2H, m, H-10), 1.47, m (2H, m, H-11), 1.37, m (2H, m, H-11'), and 3.05, m (1H, d, $J = 8.0$ Hz, H-11). Compound 3 was thus established as (E)-2-methoxy-4-(3-(methylsulfonyl)prop-1-en-1-yl)phenol.
resonance at δ 3.52 (1H, brs, H-7), and two oxygenated methine resonances at δ 4.07 (1H, brs, H-6) and 4.11 (1H, brs, H-2'). The 13C NMR spectrum (Table 1) showed fifteen carbon resonances, including two carboxyl carbons at δc 174.0 (C-3') and 168.1 (C-1), four olefinic carbons, five methylene carbons, a methine carbon resonance at δc 41.8 (C-7), and two oxygenated methine resonances at δc 67.5 (C-6) and 70.7 (C-2'). A comparison of the NMR data of 3 with those of the known compound thiosenkyunolide A suggested that these two compounds shared a similar skeleton, except in 3 C-11 bears a methyl group, while in thiosenkyunolide A, that position has a hydroxymethyl moiety. The trans configuration of C-6/7 was confirmed by comparing the chemical shifts and coupling constants seen in the 1H and 13C NMR with those of the known compounds thiosenkyunolide A (trans) and thiosenkyunolide B (cis). Further 2D NMR analysis, including HSQC and HMBC experiments (Fig. 2), confirmed the planar structure of compound 3.

Using the same method as was used for compound 1, the absolute configuration of C-2' in 3 was established by a dimolybdenum tetraacetate [Mo2(AcO)4]-induced circular dichroism procedure. The diagnostic Cotton effect at approximately 344.5 nm was negative, which indicated the absolute configuration of C-2' in 3 was S. The structure of 3 was simplified to 3Ja (6S,7S) and 3Jb (6R,7R) for convenience when calculating the ECD spectra (Fig. 3). By comparing the experimental ECD and ECD calculated based on the time-dependent density functional theory (TD-DFT) method at the B3LYP/6-31+G(d,p) level data (Fig. 4), the absolute configuration of 3 was confirmed as 6R,7R.

Finally, the structure of 3 was determined to be (3Z,3aE)-(6R,7R,2'S)-6-hydroxy-7-(2-carboxyl)-2-hydroxymethyl)-3-butylidene-4,5,6,7-tetrahydrophthalaldehyde and was named thiosenkyunolide C.

The molecular formula of compound 4 was confirmed as C21H30O12 by analysis of its HR-ESI-MS signal at m/z 497.1637 [M + Na]+ (Calcd. 497.1629). A comparison of the NMR data (Table 2) of 4 with those of the known compound 4-[β-D-apiofuranosyl-(1→6)-β-D-glucopyranosyloxy]-3-methoxypropophenone suggested that these two compounds shared a similar skeleton except for the location of their sugar moieties. In the HMBC spectrum of 4 (Fig. 4), the correlations of H-1' with C-6/C-3 suggested that an apiose moiety was attached at C-6' of the glucose moiety, and the glucose moiety was attached at C-3 of the aglycone. The configurations of the apiose and glucose were determined to both be S by GC analysis after acidic hydrolysis and chiral derivatization. The β-anomeric configurations were deduced based on the coupling constants of the anomeric protons (Glc: J = 7.5 Hz; Api: J = 3.0 Hz). Finally, compound 4 was confirmed to be 3-hydroxy-4-methoxypropophenone 3-O-β-D-apiofuranosyl-(1→6)-β-D-glucopyranoside.

Compound 5 was obtained as a white, amorphous powder, which was found to have a molecular formula of C20H28O13 based on its HR-ESI-MS signal at m/z 477.1611 [M + H]+. Its 1H NMR (Table 2) spectrum indicated an ABX system involving the benzene ring at δH 7.65 (1H, ddd, J = 8.5, 2.0 Hz, H-6), 7.49 (1H, d, J = 2.0 Hz, H-2) and 7.09 (1H, d, J = 8.5 Hz, H-5). In addition, the presence of multiple protons between δH 3.11 and δH 3.85 and two doublets at δH 5.53 (1H, d, J = 8.0 Hz, H-1') and 4.79 (1H, d, J = 3.5 Hz, H-1'') suggested the presence of two sugar moieties. The 13C NMR spectrum (Table 2) showed six aromatic carbons, an ester carbonyl carbon (δc 164.3), and two methoxy carbons. The remaining eleven carbons were indicative of an apiose moiety (δc 109.1, 78.7, 75.6, 73.2, and 62.9) and a glucose moiety (δc 94.7, 76.3, 76.2, 72.4, 69.6, and 67.3).
HMBC correlations of H-1′/C-7 and H-1″/C-6′ confirmed that the glucose moiety was attached at C-7 and the apiose was attached at C-6′ of the glucose moiety (Fig. 2). The α-configurations of the glucose and apiose were confirmed through the same method as was used for 4. The β-anomeric configurations were deduced based on the coupling constants of the anomeric protons (Glc: J = 8.0 Hz; Api: J = 3.5 Hz). In addition, the correlations of H-2/C-7, H-2′/C-4, H-5/C-3, H-6/C-2, H-OCH3 (δq 3.82)/C-3, and H-OCH3 (δq 3.84)/C-4 proved the structure of the aglycone moiety as shown. Therefore, the structure of 5 was confirmed as β-p-apiofuranosyl-(1→6)-β-d-glucopyranosyl-3,4-dimethoxy-benzoate.

The structures of two known compounds (6 and 7) were identified by comparison of their spectroscopic data with those of the known compounds. They were elucidated as 4-[β-p-apiofuranosyl-(1→6)-β-d-glucopyranosyl]-3-methoxypropiophenone and cndioside A.

All compounds were tested for their anti-inflammatory activity against LPS-induced NO production in BV2 cells and for PTP1B inhibitory activity. The results showed that 4 and 5 have strong anti-inflammatory activities with IC50 values of 2.03 and 3.09 µmol/L, respectively (positive control curcumin, IC50 = 6.17 µmol/L), and compound 1 exhibited a weak PTP1B inhibitory activity with an inhibitory rate of 19.6% at a concentration of 10 µmol/L.

3. Experimental

3.1. General experimental procedures

The optical rotations, UV spectra and ECD spectra were recorded with JASCO P-2000, V650 and J-815 spectrometers (JASCO, Easton, MD, USA), respectively. The infrared spectra were measured with JASCO P-2000, V650 and J-815 spectrometers (JASCO, Easton, MD, USA), respectively. The NMR spectra were recorded with Bruker 500 MHz spectrometers (Varian, Inc., Palo Alto, CA, USA). HR-ESI-MS (Bruker-Biospin, Billerica, MA, USA) and 600 MHz NMR spectrometers (Varian, Inc., Palo Alto, CA, USA). The infrared spectra were recorded with Bruker 500 MHz spectrometers (Varian, Inc., Palo Alto, CA, USA). The NMR spectra were recorded with Bruker 500 MHz spectrometers (Varian, Inc., Palo Alto, CA, USA). The infrared spectra were recorded withBruker 500 MHz spectrometers (Varian, Inc., Palo Alto, CA, USA). The NMR spectra were recorded with Bruker 500 MHz spectrometers (Varian, Inc., Palo Alto, CA, USA).

3.2. General experimental procedures

3.1. General experimental procedures

The optical rotations, UV spectra and ECD spectra were recorded with JASCO P-2000, V650 and J-815 spectrometers (JASCO, Easton, MD, USA), respectively. The infrared spectra were measured on Nicolet 5700 spectrometer (Thermo Scientific, FL, USA). The NMR spectra were recorded with Bruker 500 MHz spectrometers (Bruker-Biospin, Billerica, MA, USA) and 600 MHz NMR spectrometers (Varian, Inc., Palo Alto, CA, USA). HR-ESI-MS spectra were obtained using an Agilent 6520 HPLC-Q-TOF instrument (Agilent Technologies, Waldbronn, Germany). Preparative HPLC separations were performed using a Shimadzu LC-10AT with an ODS-A column (250 mm × 20 mm, 5 µm; YMC Corp., Kyoto, Japan). An Agilent 1200 series system with an Apollo C18 column (250 mm × 4.6 mm, 5 µm; Alltech Corp., KY, USA) was used for HPLC-DAD analysis. An Agilent 7890A system with a capillary column (HP-5, 60 m × 0.32 mm, with a 1 µm film; Agilent Technologies Inc., CA, USA) was used for GC analysis. Macroporous resin (Daiion HP-20, Mitsubishi Chemical Corp., Tokyo, Japan), RP-C18 (50 µm, YMC Corp., Kyoto, Japan), and Sephadex LH-20 (Pharmacia Fine Chemicals, Uppsala, Sweden) were used for column chromatography.

3.2. Plant material

The roots of *Liguisticum chuanxiong* Hort. were collected from Pengzhou Town, Sichuan Province, PRC, in June 2013 and identified by professor Lin Ma A voucher specimen (ID-S-2594) was deposited at the Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.

3.3. Extraction and isolation

The powdered rhizome of *L. chuanxiong* Hort. (100.0 kg) was exhaustively extracted with 80% EtOH at reflux. The solvent was evaporated under reduced pressure, and the residue (23.1 kg) was then successively partitioned with EtOAc and n-BuOH. The n-BuOH-soluble portion (1300 g) was separated on a macroporous resin (Daiion HP-20) column to give five fractions, A–E, using a gradient elution with H2O, 15% ethanol, 30% ethanol, 50% ethanol, and 95% ethanol. Fraction C (103.0 g) was chromatographed on an RP-C18 column eluting with H2O/MeOH (from 100:0 to 100:0) to give 16 fractions (C1–C16) based on HPLC analyses. Fraction C5 was separated by column chromatography over Sephadex LH-20 using H2O as the eluent and was further purified by preparative HPLC (MeOH/H2O; 20:80, v/v, HOAc, 0.2%) to give 4 (67 mg), 5 (5 mg), 6 (17 mg) and 7 (64 mg). Fraction C8 was separated by column chromatography over Sephadex LH-20 using H2O as the eluent and was further purified by preparative HPLC (MeOH/H2O; 30:70, v/v, HOAc, 0.2%) to give 1 (17 mg). Fraction D (48.0 g) was chromatographed on an RP-C18 column eluting with H2O/MeOH (from 95:5 to 0:100) to give 24 fractions (D1–D24) based on HPLC and TLC analyses. Fraction D9 was chromatographed over Sephadex LH-20 with a gradient of increasing MeOH (30%–100%) in H2O and was further purified by preparative HPLC (MeCN/H2O; 30:70, v/v, HOAc, 0.2%) to give 3 (2 mg).

The EtOAc-soluble portion (5.0 kg) was chromatographed on a silica gel column eluting with petroleum ether/ethyl acetate (from 100:0 to 50:50) to give 10 fractions (Ea–Ej) based on HPLC and TLC analyses. Fraction Ej (179.3 g) was separated on a silica gel column eluting with petroleum ether/ethyl acetate (from 100:1 to 1:10) to give 10 fractions (Ej1–Ej10) based on HPLC and TLC analyses. Fraction Ej5 was chromatographed over Sephadex LH-20 eluting with dichloromethane/MeOH (2:1) and was further purified by preparative HPLC (MeCN/H2O; 18:82, v/v, HOAc, 0.2%) to give 2 (18 mg).

3.3.1. (S)-2-(2-Carboxyl-2-hydroxyethylthio)-ferulic acid (1)

White, amorphous powder; [α]D20 +7.8 (c 0.10, MeOH); UV (MeOH) λmax (logε) 203 (4.22), 308 (4.07) nm; IR (KBr) νmax 3282, 2975, 2939, 1692, 1626, 1583, 1477, 1415, 1282, 1193, 1095, 948 cm−1; 1H and 13C NMR data, see Table 1; HR-ESI-MS m/z 315.0531 [M + H]+ (Calcd. for C13H15O7S, 315.0533).

3.3.2. (E)-2-Methoxy-4-(3-(methylsulfonyl)prop-1-en-1-yl)phenol (2)

White, amorphous powder; UV (MeOH) λmax (logε) 211 (3.94), 272 (3.97), 299 (3.56) nm; IR (KBr) νmax 3453, 3005, 2943, 1594, 1515, 1465, 1426, 1273, 1238, 1177, 1126, 1031, 974, 880, 822, 798, 777 cm−1; 1H and 13C NMR data, see Table 1; HR-ESI-MS m/z 265.0504 [M + Na]+ (Calcd. for C11H14O4SNa, 265.0505).

3.3.3. Thiosenkyunolide C (3)

White, amorphous powder; [α]D20 –32.0 (c 0.10, MeOH); UV (MeOH) λmax (logε) 277 (3.90) nm; IR (KBr) νmax 3364, 2961, 1747, 1414, 1242, 1093, 1047, 952 cm−1; CD (MeOH) 224 (Δε +2.01), 289 (Δε –2.67) nm; 1H and 13C NMR data, see Table 1; HR-ESI-MS m/z 329.1060 [M + H]+ (Calcd. for C15H23O6S, 329.1053).
3.3.4. 3-Hydroxy-4-methoxypropio Phenone 3-O-β-D-apiofuranosyl-(1→6)-β-D-glucopyranoside (4)

White, amorphous powder; [α]_D^20 −68.7 (c 0.10, MeOH); UV (MeOH) λ_max (log e) 201 (4.09), 224 (3.99), 271 (3.80) nm; IR (KBr) ν_max 3409, 2934, 2881, 1735, 1669, 1599, 1515, 1459, 1269, 1174, 930 cm⁻¹; 1H and 13C NMR data, see Table 2; HR-ESI-MS m/z 497.1637 [M + Na]⁺ (Calcd. for C₂₂H₃₀O₁₂Na, 497.1629).

3.3.5. β-D-Apiofuranosyl-(1→6)-β-D-glucopyranosyl-3,4-dimethoxybenzoate (5)

White, amorphous powder; [α]_D^20 −41.7 (c 0.10, MeOH); UV (MeOH) λ_max (log e) 216 (4.17), 275 (3.79) nm; IR (KBr) ν_max 3417, 2974, 2924, 1717, 1697, 1609, 1530, 1410, 1380, 1240, 1194, 975 cm⁻¹; 1H and 13C NMR data, see Table 2; HR-ESI-MS m/z 477.1611 [M + H]⁺ (Calcd. for C₂₀H₂₀O₁₃, 477.1603).

3.4. ECD calculations

Briefly, conformational analyses of 3Ja and 3Jb were carried out via systematic searching in Discovery Studio (version 16.1.0.15350) using the MMFF94 force field. Conformers with Boltzmann distributions over 1% were chosen for ECD calculations. Ground-state geometries were optimized at the B3LYP/6-31G(d,p) level in the gas phase using the Gaussian 09 program (Gaussian Inc., Wallingford, CT, USA). All quantum computations were performed on an IBM cluster machine located at the High Performance Computing Center of Peking Union Medical College. The energies, oscillator strengths, and rotational strengths (velocity) of the electronic excitations were calculated using TD-DFT methodology at the B3LYP/6-31+G(d,p) level in methanol. The calculated ECD spectra were simulated by the overlapping Gaussian function (half the bandwidth at 1/e peak height, 0.25 eV), and their lowest energy conformers were generated by Boltzmann weighting.

3.5. Anti-inflammatory activity assay

The anti-inflammatory activity was evaluated in microglial BV2 cell, which were purchased from the Cell Culture Center at the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. Curcumin was used as a positive control drug. The BV2 microglial cells were cultured at 37 °C (5% CO₂, 100% relative humidity) and maintained in DMEM containing 10% FCS (fetal calf serum). The cells were transferred to 96-well plates and treated with different samples (each compound was tested at three concentrations) after incubation for 24 h. Then, the cells in the 96-well plates were stimulated with LPS (Sigma-Aldrich) for another 24 h. Then, 100 μl aliquots of the supernatants were added to 100 μl of Griess reagent (0.1% (naphthyl)ethylenediamine and 1% sulfanilamide in a 5% H₃PO₄ solution), and the mixture was left to stand at room temperature for 20 min. NO production was measured by recording the concentration of nitrite in the supernatant. The absorbances were measured at 540 nm. Curcumin was used as the positive control drug.

3.6. PTP1B inhibitory activity assay

The pellets of recombinant GST-hPTP1B bacteria were purified on a GST bead column. The dephosphorylation of para-nitrophosphoryl phosphate (p-NPP) to para-nitrophenol was catalyzed by PTP1B. Enzyme activity using an end-point assay, which intensifies the yellow color, was measured at a wavelength of 405 nm. Compounds were dissolved in 100% dimethyl sulfoxide (DMSO). The DMSO solutions were diluted to 10% DMSO prior to use in the assays. Selected compounds were first evaluated for their ability to inhibit PTnPase at a concentration of 10 μmol/L at 30 °C for 10 min in a reaction system with 3 mmol/L p-NPP in HEPES assay buffer (pH 7.0). The reaction was initiated by the addition of the enzyme. The reaction was quenched by the addition of 1 mol/L NaOH. A microplate spectrophotometer was used to determine the amount of p-nitrophenol present.

3.7. Determination of the absolute configurations of the sugars

Compound 4 (2 mg) was dissolved in 1 mol/L CF₃COOH (14 mL), and then the mixture was heated at 70 °C for 1 h. The mixture was then extracted three times with EtOAc, and the aqueous layer was freeze-dried to obtain the residue. Using a method reported in the literature, the residue was dissolved in anhydrous pyridine (2 mL), L-cysteine methyl ester hydrochloride (4 mg) was added, and then the mixture was heated in a water bath (60 °C) for 1 h. After the reaction, the solution was dried under vacuum, N-trimethylsilylimidazole (1 mL) was added, and the solution was heated in a water bath (60 °C) for 1 h. The reaction mixture was extracted three times with H₂O/m-hexane, and the n-hexane layer was analyzed using GC under the following conditions: injection temperature, 300 °C; detector temperature (FID), 300 °C; capillary column, HP-5 (60 m × 0.32 mm, Dikma); initial oven temperature of 200 °C, increased to 260 °C at a rate of 10 °C/min, and the final temperature was maintained for 30 min; and carrier gas, N₂. Compound 5 was also evaluated by the same procedure, and all its sugars were determined to be in the α-configuration.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81773588).

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.apsb.2018.04.002.

References

1. Thomas C, Mercier F, Tournayre P, Martin JL, Berdagué JL. Identification and origin of odorous sulfur compounds in cooked ham. Food Chem 2014;155:207–13.
2. Conde-Martínez N, Sinuco DC, Osorio C. Chemical studies on curuba (Passiflora mollissima) (Kunth) L. H. Bailey) fruit flavour. Food Chem 2014;157:356–63.
3. Moreira N, De Pinho PG, Santos C, Vasconcelos I. Relationship between nitrogen content in grapes and volatiles, namely heavy sulphur compounds, in wines. Food Chem 2011;126:1599–607.
4. Schmidberger PC, Schiebel P. Characterization of the key aroma compounds in White Alba Truffle (Tuber magnatum pico) and Burgundy Truffle (Tuber uncinatum) by means of the sensomics approach. J Agric Food Chem 2017;65:9287–96.
5. Nohara T, Fujiwara Y, Kudo R, Yamaguchi K, Ikeda T, Murakami K, et al. Isolation and characterization of new onionins A₂ and A₃ from Allium cepa, and of oniosins A₁, A₃, and A₃ from Allium fistulosum. Chem Pharm Bull 2014;62:1141–5.
6. Xu K, Yang PF, Yang YN, Feng ZM, Jiang JS, Zhang PC. Direct assignment of the Three and Ervynho configurations in polyacetylene glycosides by $^1$H NMR spectroscopy. Org Lett 2017;19:686–9.

7. Siddique YH, Beg T, Ara G, Gupta J, Afzal M. Antigenotoxic effect of allicin against estradiol-17β-induced genotoxic damage in cultured mammalian cells. Nat Prod Res 2010;24:1087–94.

8. Nikitina LE, Artemova NP, Staritseva VA, Fedyunina IV, Klochkov VV. Biological activity of $S$-containing monoterpenoids. Chem Nat Compd 2017;53:811–9.

9. Slavikova B, Chodounska H, Nekardova M, Vyklicky V, Ladislav M, Hubalkova P, et al. Neurosteroid-like inhibitors of N-methyl-o-aspartate receptor: substituted 2-sulfates and 2-hemisuccinates of phthalide derivatives. J Med Chem 2013;56:5523–30.

10. Li CM, Guo YQ, Dong XL, Li H, Wang B, Wu JH, et al. Ethanolic extract of rhizome of Ligusticum chuanxiong from Chuanxiong 2005; Planta Med 2012;68:321–6.

11. Li BH, Xu X, Wang X, Yu H, Li XX, Tao WY, et al. A systems biology approach to understanding the mechanisms of action of Chinese herbs for treatment of cardiovascular disease. Int J Mol Sci 2012;13:13501–20.

12. Liu L, Ning QZ, Shan S, Zhang K, Deng T, Lu XP, et al. Phthalide lactones from Ligusticum chuanxiong inhibit lipopolysaccharide-induced TNF-α production and TNF-α-mediated NF-κB activation. Planta Med 2005;71:808–13.

13. Xie X, Tian Y, Yin S, Lin Y, Tan G. Anticancer effects of Ligusticum chuanxiong Hert. (chuanxiong) enhances endothelium-dependent vasorelaxation in ovariectomized rats fed with high-fat diet. Food Funct 2014;5:2475–85.

14. Sun K, Fan JY, Han JY. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage. Acta Pharm Sin B 2015;5:8–24.

15. Huang J, Lu XQ, Zhang C, Lu J, Li GY, Lin RC, et al. Anti-inflammatory ligustilides from Ligusticum chuanxiong Hert. Fitoterapia 2013;91:21–7.

16. Miao CP, Wu SH, Luo BZ, Wang J, Chen YW. A new sesquiterpenoid from Ligusticum chuanxiong Hert. Fitoterapia 2010;81:1088–90.

17. Lim LS, Shen P, Gong YH, Yong EL. Dimeric progestins from rhizomes of Ligusticum chuanxiong. Phytochemistry 2006;67:728–34.

18. Huang J, Lu XQ, Lu J, Li GY, Wang HY, Li LH, et al. Two new phthalides with BuChE inhibitory activity from Ligusticum chuanxiong. J Asian Nat Prod Res 2013;15:1237–42.

19. Yang NY, Ren DC, Duan JA, Xu XH, Xie N, Tian LJ. Ceramides and cerebrosides from Ligusticum chuanxiong Hert. Helv Chim Acta 2009;92:291–7.

20. Kim M, Kim SO, Lee M, Lee JH, Jung WS, Moon SW, et al. Tetramethylpyrazine, a natural alkaloid, attenuates pro-inflammatory mediators induced by amyloid β and interferon-γ in rat brain microglia. Eur J Pharmacol 2014;740:504–11.

21. Li SL, Chan SSK, Lin G, Ling L, Yan R, Chung HS, et al. Simultaneous analysis of seventeen chemical ingredients of Ligusticum chuanxiong by on-line high performance liquid chromatography-diode array detector-mass spectrometry. Planta Med 2003;69:445–51.

22. Li YH, Peng SL, Zhou Y, Yu KB, Ding LS. Two new phthalides from Ligusticum chuanxiong. Planta Med 2006;72:652–6.

23. Naito T, Katsuura T, Niitsu K, Ikeya Y, Okada M, Mitsuhashi H. Two phthalides from Ligusticum chuanxiong. Phytochemistry 1992;31:639–42.

24. Naito T, Niitsu K, Ikeya Y, Okada M, Mitsuhashi H. A phthalide and 2-farnesyl-6-methyl benzoquinone from Ligusticum chuanxiong. Phytochemistry 1992;31:1787–9.

25. Naito T, Ikeya Y, Okada M, Mitsuhashi H, Maruno M. Two phthalides from Ligusticum chuanxiong. Phytochemistry 1996;41:233–6.

26. Yang J, Feng XL, Yu Y, Wang Q, Zou J, Wang CX, et al. Novel phthalide derivatives identified from Ligusticum chuanxiong (Chuan- xiong). Chin Med 2016;11:10.

27. Wei W, Xu W, Yang XW. Two new phthalide dimers from the rhizomes of Ligusticum chuanxiong. J Asian Nat Prod Res 2017;19:704–11.

28. Wei W, Wu XW, Yang XW. Novel phthalide derivatives from the rhizomes of Ligusticum chuanxiong and their inhibitory effect against lipopolysaccharide-induced nitric oxide production in RAW 264.7 macrophage cells. RSC Adv 2016;6:61037–46.

29. Zhang X, Han B, Feng ZM, Yang YN, Jiang JS, Zhang PC. Phthalide derivatives from Ligusticum chuanxiong. RSC Adv 2017;7:37478–86.

30. Chang XL, Jiang ZY, Wu SH, Zhang XM, Tism KWK, Chen JJ. Two new compounds from the roots of Ligusticum chuanxiong. J Asian Nat Prod Res 2011;9:1085–10.

31. Snatzke G, Wagner U, Wolff HP. Circulardichroism—LXXV1; cottonogenic derivatives of chiral bidentate ligands with the complex [Mo2(O2CCH3)4]. Tetrahedron 1981;37:349–61.

32. Yuan Z, Tezuka Y, Fan W, Kadota S, Li X. Constituents of the underground parts of Glehnia littoralis. Chem Pharm Bull 2002;50:73–7.

33. Chem CC, Huang YL, Huang H, Wang CW, Ou JC. Water-soluble glycosides from Ruta graveolens. J Nat Prod 2001;64:990–2.

34. Gan ML, Liu MT, Gan LS, Liu B, Zhang YL, et al. Dammarane glycosides from the root of Machilus yatsushan. J Nat Prod 2012;75:1373–82.